Acquired resistance to conventional chemotherapies and/or tumor escape from immune control often lead to failure of cancer therapy. The LIIC research team focuses on the antitumor properties of nitric oxide (NO), as a sensitizer of cancer cells to death, when used in combination with standard chemotherapeutic agents (Axes of research 1 to 3) or with new immunotherapies (Axes of research 3 and 4).
